NDRC

AML Enforcement Priorities Have Implications Across Several Sectors

China’s National Development and Reform Commission (NDRC) recently announced its 2018 priorities for pricing investigations under the anti-monopoly law (AML), listing key industries in which it says price-fixing tactics impact the day-to-day lives of Chinese citizens.

Tags

AML

Is China’s Antimonopoly Campaign Ramping Up Again?

Enforcement of China’s Antimonopoly Law (AML)—an ongoing priority for the US-China Business Council (USCBC) and the business community—has remained prominent in recent bilateral discussions. AML-related issues featured among the outcomes reached during last month’s state visit to the United States by Chinese President Xi Jinping, as well as in USCBC meetings in Beijing with senior officials from China’s three antitrust agencies.

Tags

AML

Reform in China’s Pharmaceuticals Sector - What the Doctor Ordered?

Fewer restrictions on drug pricing and greater access for foreign companies may make for a healthier China, and bring both potential growth and growing pains to the pharmaceutical industry—a sector analysts expect to be worth upwards of $300 billion by 2020.

Tags

R&D

NDRC 'Actively' Investigating AML Cases Despite Media Silence

A lack of recent news about competition-related investigation cases should not be misinterpreted as a lull in enforcement activity related to China’s Antimonopoly Law (AML), a National Development and Reform Commission (NDRC) official stated at a recent USCBC-sponsored event.

Tags

AML
IP
Subscribe to RSS - NDRC